Health Care & Life Sciences » Biotechnology | Alexion Pharmaceuticals Inc.

Alexion Pharmaceuticals Inc. | Cash Flow

Fiscal year is January-December. All values USD Millions.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
253
657
144
399
443
78
Depreciation, Depletion & Amortization
27
47
161
386
488
397
Other Funds
102
251
119
68
44
352
Funds from Operations
493
483
1,090
1,222
1,286
860
Changes in Working Capital
4
157
415
136
171
434
Net Operating Cash Flow
497
640
675
1,086
1,116
426
Capital Expenditures
29
174
286
333
357
Purchase/Sale of Investments
988
48
635
47
561
Net Investing Cash Flow
1,027
223
3,585
287
918
Issuance/Reduction of Debt, Net
36
56
3,354
375
175
Net Financing Cash Flow
72
7
2,985
836
597
Net Change in Cash
460
414
66
44
382
Free Cash Flow
468
503
389
753
758
Deferred Taxes & Investment Tax Credit
93
154
395
104
46
33
Net Assets from Acquisitions
-
-
3,939
-
-
Other Sources
-
-
-
5
-
Change in Capital Stock
5
188
250
393
378
Exchange Rate Effect
1
10
9
7
18
Other Uses
9
1
-
1
-

About Alexion Pharmaceuticals

View Profile
Address
121 Seaport Boulevard
Boston Massachusetts 02210
United States
Employees -
Website http://www.alexion.com
Updated 07/08/2019
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include soliris, strensiq and kanuma. The company was founded by Joseph A.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.